STOCK TITAN

Roivant Sciences (ROIV) director gets share grant with tax netting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Roivant Sciences Ltd. director James C. Momtazee reported routine equity compensation activity. He received 469 Common Shares as an award under Roivant’s Non-Employee Director Compensation Plan, which were fully vested on the grant date. To cover related tax withholding obligations, 94 previously granted Common Shares were net-settled back to the company. After these transactions, he directly holds 109,499 Common Shares. These entries reflect compensation and tax withholding mechanics rather than open-market buying or selling.

Positive

  • None.

Negative

  • None.
Insider MOMTAZEE JAMES C
Role null
Type Security Shares Price Value
Grant/Award Common Shares 469 $0.00 --
Tax Withholding Common Shares 94 $29.83 $3K
Holdings After Transaction: Common Shares — 109,499 shares (Direct, null)
Footnotes (1)
  1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.
Share award 469 Common Shares Fully vested grant under Non-Employee Director Compensation Plan
Tax-withholding shares 94 Common Shares Net settlement to satisfy tax withholding obligations
Post-transaction holdings 109,499 Common Shares Direct ownership after reported Form 4 transactions
Reference price per share $29.83 per share Value used for 94-share tax-withholding disposition
Non-Employee Director Compensation Plan financial
"received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested"
net settlement financial
"Represents the "net settlement" by the Issuer of Common Shares previously granted"
tax withholding obligations financial
"in order to satisfy applicable tax withholding obligations in connection with the vesting"
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MOMTAZEE JAMES C

(Last)(First)(Middle)
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY

(Street)
LONDONSW1H 0DB

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares04/17/2026A469(1)A$0(1)109,499D
Common Shares04/17/2026F94(2)D$29.83109,405D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.
2. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.
Remarks:
By: /s/ Jo Chen, as Attorney-in-Fact for James C Momtazee04/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Roivant Sciences (ROIV) director James C. Momtazee report?

James C. Momtazee reported a routine equity award and related tax withholding. He received 469 Roivant Common Shares and 94 previously granted shares were net-settled back to the issuer to satisfy tax obligations tied to vesting.

Were James C. Momtazee’s Roivant (ROIV) Form 4 transactions open-market trades?

No. The Form 4 shows a fully vested share award and tax withholding, not open-market trades. The 469-share grant and 94-share net settlement arose under Roivant’s Non-Employee Director Compensation Plan, reflecting compensation mechanics rather than discretionary buying or selling.

How many Roivant (ROIV) shares does James C. Momtazee hold after this Form 4?

After the reported transactions, James C. Momtazee directly holds 109,499 Roivant Common Shares. This figure reflects the impact of receiving 469 fully vested shares and the 94-share net settlement for tax withholding under the company’s director compensation plan.

What does the 469-share award to Roivant (ROIV) director Momtazee represent?

The 469 Roivant Common Shares represent an equity award under the Non-Employee Director Compensation Plan. According to the filing, the award was fully vested on the grant date, indicating immediate ownership rights as part of standard non-employee director compensation.

Why were 94 Roivant (ROIV) shares disposed of in James C. Momtazee’s Form 4?

The 94 Roivant shares were net-settled to satisfy tax withholding obligations on vested shares. The filing explains this as payment of tax liability by delivering securities, a common method for covering taxes on equity compensation without an open-market sale.